SYRA HEALTH CORP A (SYRA) Financials

SYRA HEALTH CORP A (SYRA) reported diluted earnings per share of -$0.08 for fiscal year 2025. This represents a 84.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

SYRA HEALTH CORP A (SYRA) had EBITDA of -$884K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

SYRA HEALTH CORP A (SYRA) had a gross margin of 34.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

SYRA HEALTH CORP A (SYRA) had an operating margin of -12.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

SYRA HEALTH CORP A (SYRA) had a net profit margin of -12.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

SYRA HEALTH CORP A (SYRA) has a return on equity of -42.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

SYRA HEALTH CORP A (SYRA) recorded an outflow of $448K in free cash flow during fiscal year 2025. This represents a 84.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

SYRA HEALTH CORP A (SYRA) recorded an outflow of $448K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

SYRA HEALTH CORP A (SYRA) had $2.8M in total assets as of fiscal year 2025, including both current and long-term assets.

SYRA HEALTH CORP A (SYRA) invested $107 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

SYRA HEALTH CORP A (SYRA) invested $68K in research and development during fiscal year 2025.

SYRA HEALTH CORP A (SYRA) had 11M shares outstanding as of fiscal year 2025.

SYRA HEALTH CORP A (SYRA) had a current ratio of 4.06 as of fiscal year 2025, which is generally considered healthy.

SYRA HEALTH CORP A (SYRA) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

SYRA HEALTH CORP A (SYRA) had a return on assets of -32.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

SYRA HEALTH CORP A (SYRA) trades at 93.3x earnings, its market capitalization divided by net income of $131K net income, trailing 12 months to June 30, 2026. The market capitalization is $12.2M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

SYRA HEALTH CORP A (SYRA) trades at 1.5x sales, its market capitalization divided by revenue of $8.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $12.2M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, SYRA HEALTH CORP A (SYRA) held $1.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $448K over that year. Dividing the one by the other, the reported balance equals about 43 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

SYRA HEALTH CORP A (SYRA) has an Altman Z-Score of 8.37, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

SYRA HEALTH CORP A (SYRA) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

SYRA HEALTH CORP A (SYRA) reported a net loss of $896K while operations used $448K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

SYRA HEALTH CORP A (SYRA) reported an operating loss of $904K against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.